Marietta Wu

Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.

Jing Medicine Technology Shanghai Ltd. develops therapeutic monoclonal antibody and small molecule drugs. The private company is based in Shanghai, China.

MEDx Translational Medicine Co., Ltd. is a leading Chinese innovative company in companion diagnostics and precision medicine in China. The company is based in Suzhou, China. MEDx collaborates with hundreds of world-renowned pharmaceutical companies and has been rewarded with many certifications, including China CNAS, ISO17025, and US CAP ISO 13485, among others. The company was founded in 2013 as Qiagen Translational Medicine Co., Ltd. With comprehensive technology platforms, high-quality systems, and strong IVD R&D experience, MEDx offers integrated solutions from biomarker discovery to patient stratification for drug clinical trials, IVD/CDX R&D, and commercialization. The company was founded in 2013 by Ya Fei Zhang, who has been the CEO since then.

Kira Pharmaceuticals (Hong Kong) Ltd. manufactures pharmaceuticals. The private company is based in Hong Kong, Hong Kong.

Innoforce Pharmaceuticals Co. Ltd. is a bioinnovation-enabling corporation located in the Hangzhou Bay Biotech Valley within the Hangzhou Airport Economic Demonstration Area. The founders and core management team have extensive international experience and expertise in technology innovation, product development, and business operations. The Chinese company's first phase of the campus covers 21 acres, including biologic process development laboratories, scale-up and R & D labs, and manufacturing facilities for protein, cell, and gene therapies. The company was founded in 2018 by Guo-Liang Yu, Yuling Li, and Zhenhua Wu. Dewan Zeng has been the CEO of the company since 2023.

Shanghai Rarestone Health Tech Group Co. Ltd. is a Chinese company that focuses on rare disease therapy and self-management information through internet information. The company is based in Huangpu, China. The company also operates and promote medical devices and communication platforms. The CEO of the company is Shawn Xiang.

Eluminex Biosciences (Suzhou) Ltd. is a privately held biotechnology company located in Suzhou, China. Eluminex Biosciences is committed to developing innovative pharmaceuticals, drug delivery systems, and regenerative tissue for significant unmet vision-threatening or lifestyle limiting ophthalmic diseases in various markets. The Chinese company focuses on ophthalmology and recombinant human collagen technology, with a goal to become a leading healthcare company in developing irreversible loss of optical quality of the cornea due to disease or damage, diabetic macular edema, and wet age-related macular degeneration. The company was founded in 2020 by Jin Zhong Zhang, who has been the CEO since then.